Through regulating pathways such as EGFR, MAPK/ERK, and PI3K/AKT, COL6A2 contributes to epithelial-mesenchymal transition (EMT), drug resistance, and immune evasion, thereby promoting tumor invasiveness and correlating with poor prognosis. Here, COL6A2 is linked to neoplasm.